PatentApr 30, 2026, 08:09 AM
GNPX Granted Israel Patent for Reqorsa® Gene Therapy
AI Summary
Genprex, Inc. announced that the Israel Patent Office has granted a patent for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for use in combination with PD-1 antibodies for cancer treatment. This strategic expansion builds upon the company's existing intellectual property in numerous major markets worldwide. Reqorsa is initially being developed for lung cancer, a significant health concern in Israel, where lung cancer cases increased by 33% within a decade by 2020 and was the leading cause of cancer death in 2021.
Key Highlights
- Israel Patent Office granted Genprex a patent for Reqorsa® Gene Therapy.
- Patent covers Reqorsa® in combination with PD-1 antibodies for cancer treatment.
- Expands Genprex's existing intellectual property in major markets globally.
- Reqorsa® is initially being developed to treat lung cancer.
- Lung cancer cases in Israel increased by 33% within a decade by 2020.
- Lung cancer was the number one cancer death cause in Israel in 2021.
Price Impact
More from GNPX